

# Quick-Med Technologies, Inc.



QuickMedTechnologies

<b>Founded:</b>	1997
<b>Ownership</b>	Publicly traded (OTCQB: QMDT); 37 million shares outstanding; insider holdings of 35% (as of December 31, 2011)
<b>Management Team:</b>	Bernd Liesenfeld, Ph.D., President William Toreki, Ph.D., Vice President, Research & Development
<b>Company:</b>	Quick-Med Technologies, Inc. is an innovative life sciences company specializing in the development of next-generation technologies for the healthcare and consumer markets.
<b>Technology:</b>	<p>Quick-Med has developed the world's most advanced antimicrobial technologies. They combat microbial growth by employing an irreversibly bound, non-leaching active agent that attacks bacteria by destabilizing the microbe's cell wall. Because the active agent is permanently bonded to the substrate, the biocide does not deplete while controlling both Gram-positive and Gram-negative microbes (including MRSA, VRE, and other difficult strains). Our non-leaching technology means the active is not depleted and therefore not prone to conditions that give rise to the development of resistant strains. And because there's no leaching, our technologies don't pose the environmental and safety concerns associated with traditional antimicrobials. Our cutting-edge antimicrobials are safe, highly effective, rapid-acting and long-lasting, and can be deployed at very affordable costs.</p> <p>Additionally, Quick-Med's MultiStat<sup>®</sup> compounds have been shown to be highly effective in reducing the causes of skin wrinkling and aging. These matrix metalloproteinase inhibitor (MMPI) compounds are 1,000 times more potent than the natural MMPIs that present in human blood for the maintenance and repair of skin and eye tissue. Our compounds are the active ingredient in commercial anti-aging creams; we have also conducted government-funded research for MultiStat in advanced wound care and as anti-terrorism remedy.</p>
<b>Business Model:</b>	Quick-Med Technologies' primary business model is built around the twin pillars of <i>technology development</i> and <i>out-licensing</i> . The Company has a high-margin model with low infrastructure needs. Quick-Med also has a multi-year Manufacturing and Distribution Agreement with BASF to commercialize our MultiStat technology in the OTC cosmetics market segment. And, we selectively undertake government-funded research where there is alignment between the government interests and our business objectives.
<b>Target Markets:</b>	Quick-Med has initially targeted the <i>health care</i> market where there is strong recognition of the value of antimicrobials, growing safety and environmental concerns associated with market-leading silver antimicrobials, and we have received FDA clearance. We are developing break-through, highly durable formulations for <i>textiles and apparel</i> where today's antimicrobials lack the ability to maintain efficacy through repeated laundering and we have received EPA registration. Our proprietary, persistent hand sanitizer technology is aimed at revolutionizing the <i>hand sanitizer</i> product category. Our MMPI technology offers key advantages for <i>skin care</i> applications and significant promise for <i>advanced wound care</i> .
<b>Contact Information:</b>	902 N.W. Fourth Street; Gainesville, FL 32601 • <a href="http://www.quickmedtech.com">www.quickmedtech.com</a> Bernd Liesenfeld, Ph.D., President ( <a href="mailto:bliesenfeld@quickmedtech.com">bliesenfeld@quickmedtech.com</a> ; 352-379-0611)